🇺🇸 FDA
Patent

US 10961232

Substituted pyrazines as ATR kinase inhibitors

granted A61PA61P35/00

Quick answer

US patent 10961232 (Substituted pyrazines as ATR kinase inhibitors) held by Vertex Pharmaceuticals Incorporated expires Mon Mar 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Mar 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61P, A61P35/00